Prestige Consumer Healthcare Inc. (PBH) Stock Score, Valuation & Financial Research
Prestige Consumer Healthcare Inc. is in the Healthcare sector and Medical - Pharmaceuticals industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 43/100.
Quick answer for PBH
Prestige Consumer Healthcare Inc. currently has a Wall Street Score of 43/100. The stored market price is $47.34. Its financial score is 23/100. Its valuation score is 26/100. These figures are a research snapshot, not a buy or sell recommendation.
What Prestige Consumer Healthcare Inc. does
Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), femin
PBH financial snapshot
- Wall Street Score:
- 43/100
- Current price:
- $47.34
- Market capitalization:
- $2.24B
- Revenue:
- $1.09B
- Net income:
- $190.3M
- Free cash flow:
- $254.2M
- Cash:
- $63.9M
- Total debt:
- $1.05B
- EPS:
- 3.93
- P/E ratio:
- 12.0x
- Financial score:
- 23/100
- Valuation score:
- 26/100
- Revenue score:
- 20/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $254.2M, showing positive cash generation.
- The balance sheet shows $63.9M of cash versus $1.05B of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 26/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 23/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research PBH
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.